{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D. ","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/bfa59a47\"></iframe>","width":"100%","height":180,"duration":669,"description":"In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.During their conversation, Dr. Morice and Dr. Tan explore:Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARK® from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements.","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}